New combo tackles tough lymphomas
NCT ID NCT03150329
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests the safety and best dose of combining two drugs—pembrolizumab (Keytruda) and vorinostat (Zolinza)—in people with certain lymphomas that have returned or not responded to treatment. Pembrolizumab helps the immune system attack cancer cells, while vorinostat blocks enzymes that help cancer grow. The study involves 52 participants and aims to find the safest dose and see how well the combination works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda) and vorinostat (Zolinza)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with certain lymphomas that have stopped responding to standard therapies.
- What could go wrong
- This is a very early (Phase 1) trial with only 52 participants, focused on safety and dosing. The combination may not prove effective or may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE B-CELL LYMPHOMA UNCLASSIFIED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Can a single shot build a cancer army inside the body?
- New drug combo aims to tame aggressive lymphoma in frail patients
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma